S-488210 / Shionogi, OncoTherapy - LARVOL DELTA

First-in-human Study of S-588210 (S-488210+S-488211) (clinicaltrials.gov) - P1; N=10; Recruiting; Sponsor: Shionogi

Clinical • New P1 trial

DURANCE: DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (clinicaltrials.gov) - P1/2; N=64; Not yet recruiting; Sponsor: University College, London; Initiation date: Dec 2019 ➔ Mar 2020

Clinical • Combination therapy • Trial initiation date • PCR • PD-L1 • TIL

DURANCE: DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (clinicaltrials.gov) - P1/2; N=64; Not yet recruiting; Sponsor: University College, London

Clinical • Combination therapy • New P1/2 trial